Find insight on Pfizer, Mankind Pharma and more in the latest Market Talks covering the Health Care sector.

Pfizer said on Wednesday its experimental gene therapy for a type of muscle-wasting disorder did not meet the main goal of a ...

Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with ...

Shares of Sarepta Therapeutics climbed early Thursday after a potential competitor to its gene therapy stumbled in a ...

During a recent investor event dedicated to the newly expanded oncology business, Pfizer unveiled a goal to have ...

Pfizer's challenging period may be turning around with strong Q1 performance and potential changes under new leadership.

With a phase 3 miss following a fatality in a related study and marking what analysts are calling the “final nail” in ...

The CIFFREO study is under a dosing pause due to a fatal serious adverse event reported in the Phase II DAYLIGHT trial.

There’s that widely publicized $35 cap on insulin prices — but who came up with that magic number? Both Presidents Trump and ...

Sarepta, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments, saw its stock rise on Thursday after a ...

Pfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor function for boys with ...